A5101404820- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Bone health and treatments
- Cancer, Lipids, and Metabolism
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Estrogen and related hormone effects
- Renal cell carcinoma treatment
- HER2/EGFR in Cancer Research
- Urologic and reproductive health conditions
- Advanced Breast Cancer Therapies
- Cancer-related cognitive impairment studies
- Pancreatic and Hepatic Oncology Research
- Cancer survivorship and care
- Management of metastatic bone disease
- Testicular diseases and treatments
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- Bladder and Urothelial Cancer Treatments
- COVID-19 Clinical Research Studies
- Chemotherapy-related skin toxicity
- Neuroblastoma Research and Treatments
Lawson Health Research Institute
2020-2024
Western University
2018-2024
London Health Sciences Centre
2019-2024
Victoria Hospital
2024
Western University of Health Sciences
2019
Hospital Santa Marcelina
2019
Ottawa Hospital
2016-2018
University of Ottawa
2016-2018
University of Oxford
2018
The treatment landscape of genitourinary cancers has significantly evolved over the past few years. Renal cell carcinoma, bladder cancer, and prostate cancer are most common malignancies. Recent advancements have produced new targeted therapies, particularly antibody–drug conjugates (ADCs), due to a better understanding underlying oncogenic factors molecular mechanisms involved. ADCs function as ‘drug delivery into tumor’ system. They composed an antigen-directed antibody linked cytotoxic...
Clinical variables may correlate with lack of response to treatment (primary resistance) or clinical benefit in patients clear cell renal carcinoma (ccRCC) treated anti-programmed death 1/ligand one antibodies.In this multi-institutional collaboration, characteristics primary resistance (defined as progression on initial computed tomography scan) were compared using Two sample t-test and Chi-square test (or Fisher's Exact test). The Kaplan-Meier method was used estimate the distribution...
Abstract Background: Patients with a/mTNBC have limited treatment options and a poor prognosis (objective response rate [ORR] of 37%, median duration 6.5 months, overall survival 15.5 months for 1L chemotherapy [Rugo, et al. Ann Oncol. 2021 LBA16]). Combining checkpoint inhibitors modestly improves outcomes but only in PD-L1–positive a/mTNBC, emphasizing critical unmet need patients PD-L1–negative disease further improving disease. BEGONIA (NCT03742102) is an ongoing 2-part, open-label...
•Multicentre randomised trial of 466 breast cancer patients compared schedules filgrastim administration.•Provides real-world data showing use beyond 5 days did not significantly improve co-primary or secondary outcomes.•5 should be considered the standard care. BackgroundThe optimal duration as primary febrile neutropenia (FN) prophylaxis in early is unknown, with 5, 7 10 being commonly prescribed. This evaluates whether was non-inferior to 7/10 days.Patients and methodsIn this randomised,...
Early treatment intensification with neoadjuvant therapy may improve outcomes in patients high-risk, localized prostate cancer treated radical prostatectomy. Our objective was to compare pathologic, oncologic, and safety of abiraterone acetate plus leuprolide or without cabazitaxel prior prostatectomy localized, high-risk cancer.This open-label, multicenter, phase II trial randomized men clinically D'Amico (1,000 mg/day) (22.5 mg every 3 months) (25 mg/m2) The primary outcome pathologic...
Studies evaluating a relationship of vitamin D in patients with primary melanoma have consistently identified an inverse correlation Breslow thickness, but inconsistent impact on survival. Vitamin later stages has been less studied.
4553 Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved with the advent either dual immune checkpoint inhibition (ICI) or in combination Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor. Gut microbiota plays a central role developing local and systemic immunity, potential influence controlling anti-tumor response cancer patients treated ICI. We hypothesize that FMT from healthy donors given before immunotherapy will establish more...
We present a case of 60-year-old male diagnosed with metastatic clear cell renal carcinoma who developed hypoglycemia during induction ipilimumab and nivolumab treatment. This was as presumed type 1 diabetes mellitus secondary to immunotherapy.
Extragonadal germ cell tumors account for 2–5.7% of (GCTs). Of these, primary mediastinal GCTs (PMGCTs) are responsible 16–36% cases. Given the rarity these tumors, specific treatment strategies have not been well defined. We report our experience in treating complex patients. In total, 318 men treated at institution with chemotherapy between 1980 and 2016 were reviewed. PMGCT was defined as clinically diagnosed GCT no evidence testicular (physical exam/ultrasound). identified nine patients...
Bone metastases are a significant source of morbidity and mortality for patients with breast prostate cancer. In this review, we discuss key practical themes regarding the use bone-targeted agents (btas) such as bisphosphonates denosumab managing bony metastatic disease. The btas both delay onset reduce incidence skeletal-related events (sres), defined any or all need radiation therapy surgery to bone, pathologic fracture, spinal cord compression, hypercalcemia malignancy. They have more...
Neither paclitaxel plus trastuzumab (P-H) nor docetaxel-cyclophosphamide (TC-H) have been prospectively compared in HER2-positive early-stage breast cancer (EBC). A randomized trial was performed to assess the feasibility of a larger study.Lower-risk EBC patients were either P-H or TC-H treatment arms. The co-primary outcomes were: ≥75% patient acceptability rate, active participation ≥50% medical oncologists, and ≥90% completion, receipt rate planned cycles chemotherapy,...
Abstract Purpose Machine learning (ML) is a powerful tool for interrogating datasets and relationships between multiple variables. We utilized ML model to identify those early breast cancer (EBC) patients at highest risk of developing severe vasomotor symptoms (VMS). Methods A gradient boosted decision utilizing cross-sectional survey data from 360 EBC was created. Seventeen patient- treatment-specific variables were considered in the model. The outcome variable based on Hot Flush Night...